sarpogrelate has been researched along with Edema, Cardiac in 1 studies
sarpogrelate: structure given in first source
Edema, Cardiac: Abnormal fluid retention by the body due to impaired cardiac function or heart failure. It is usually characterized by increase in venous and capillary pressure, and swollen legs when standing. It is different from the generalized edema caused by renal dysfunction (NEPHROTIC SYNDROME).
| Excerpt | Relevance | Reference |
|---|---|---|
| "Sarpogrelate (4 mg/kg) was infused intravenously for 30 min either before LCA occlusion or at reperfusion." | 1.33 | 5-HT2 receptor blocker sarpogrelate prevents downregulation of antiapoptotic protein Bcl-2 and protects the heart against ischemia-reperfusion injury. ( Maeda, H; Murio, Y; Rajesh, KG; Sasaguri, S; Suzuki, R, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Rajesh, KG | 1 |
| Suzuki, R | 1 |
| Maeda, H | 1 |
| Murio, Y | 1 |
| Sasaguri, S | 1 |
1 other study available for sarpogrelate and Edema, Cardiac
| Article | Year |
|---|---|
5-HT2 receptor blocker sarpogrelate prevents downregulation of antiapoptotic protein Bcl-2 and protects the heart against ischemia-reperfusion injury.
Topics: Animals; Apoptosis; Cardiotonic Agents; Caspase 3; Caspases; Down-Regulation; Edema, Cardiac; Heart; | 2006 |